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Background: Tetrapleura tetraptera, a seasoning and nutritive spice is also used in western African folk medicine in the
management of wide variety of diseases including diabetes, inflammation and hypertension. Flavonoids and saponins
are some abundant secondary metabolic constituents in the fruits of this plant. This study aimed at evaluating the
potential therapeutic action of the polyphenol-rich hydroethanolic extract (HET) of this fruit in experimentally induced
obese and type 2 diabetic rats (T2DM) with characteristic metabolic syndrome (MetS).
Methods: MetS was induced in rats by high-carbohydrate, high-fat diet and administration of low-dose streptozotocin.
Then different oral doses of HET (200 and 400 mg/kg) were administered to T2DM rats for 28 days. A standard antidiabetic
drug, metformin (300 mg/kg), was used for comparison. The body weight, systolic blood pressure, oxidative stress and
metabolic parameters were then assessed to evaluate the effect of HET on MetS.
Results: HET reduced weight gain, fasting blood glucose and plasma insulin levels as well as homeostasis model
assessment of insulin resistance (HOMA-IR) and alleviated obesity and T2DM associated oxidative stress and hypertension
in rats. Moreover, a significantly hypolipidemic property and an attenuation of liver injury and tissue steatosis was
observed after HET administration. HET further demonstrated its anti-inflammation effect via down regulation of tumor
necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), C-reactive protein (CRP), leptin and an increase in adiponectin. The HET
exhibited dose-dependent effects which were comparable to that of metformin.
Conclusions: The present study thereby demonstrates the anti-insulin resistance, antilipidemic, anti-obesity, hypotensive
and anti-inflammatory properties of HET; hence it has the potential to be further developed for the management of MetS
such as obesity, T2DM and hypertension.
Keyword: Obesity, Type 2 diabetes, High-carbohydrate high-fat diet, Metabolic syndrome, Inflammation, Tetrapleura
tetraptera* Correspondence: kuatedie@msu.edu
1Program in Nutrition, School of Health Sciences Universiti Sains Malaysia,
Kubang Kerian, Kelantan 16150, Malaysia
2Department of biochemistry, Faculty of science, University of Dschang, PO
Box 67, Dschang, Cameroon
Full list of author information is available at the end of the article
© 2015 Kuate et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Kuate et al. Lipids in Health and Disease  (2015) 14:50 Page 2 of 13Introduction
Obesity, diabetes and hypertension are increasingly
common human health conditions which are referred
to as metabolic syndrome. Metablic syndrome is de-
fined as the clustering of risk factors for cardiovascular
disease and type 2 diabetes increases cardiovascular
mortality. Diabetes mellitus, is the most common meta-
bolic disorder characterized by impaired homeostasis of
carbohydrate, protein, and fat metabolism which ultim-
ately lead to persistent elevated blood glucose levels.
The most recent estimates of International Diabetes
Federation (IDF) indicate that 8.3 % of adults – 382
million people – have diabetes in 2013, and the number
of people with the disease is set to rise beyond 592 mil-
lion by 2035, if current demographic patterns continue
[1]. The underlying cause of diabetes is either decrease
in the synthesis/secretion of insulin (type 1 diabetes
mellitus (T1DM)) or by insulin resistance, followed
later by death of pancreas’ β-cells (T2DM). T2DM
which constitutes the vast majority of diabetes is a het-
erogeneous disorder characterized by impairment of in-
sulin sensitivity, followed by the inability of pancreatic
β cells to compensate for insulin resistance (pancreatic
beta cell dysfunction) [2].
Obesity results from rapid urbanization, western-
style high-fat high-carbohydrate diet and a sedentary
lifestyle. Visceral obesity is the major risk factor con-
tributing to the development of insulin resistance. In
addition, oxidative stress resulting from persistent
hyperglycemia, contributes to the vicious cycle of
insulin resistance and low-grade inflammation, charac-
terized by changes in biochemical markers of inflam-
mation and the activation of some proinflammatory
signaling pathways [2]. All these biochemical changes
are often concomitant with excess lipid accumulation
in adipose tissues [3]. Infiltrated immune cells enhance
the low-grade inflammation in adipose tissues, and the
increased inflammatory cytokines subsequently stimu-
late insulin resistance and inflammation in other
organs such as the skeletal muscle and liver [4]. Hyper-
lipidemia, hyperglycemia, inflammation and oxidative
stress are therefore playing an important role in the
pathogenesis of T2DM, leading to the development of
microvascular and macrovascular complications of
diabetes, which further contribute to the morbidities
and mortalities related to T2DM and cardiovascular
diseases [5]. Thus, besides controlling weight and
hyperglycemia, efficient amelioration of dyslipidemia,
inflammation and oxidative stress are important fac-
tors in clinical treatment of obesity and T2DM. The
drugs currently used as antidiabetic medicines include
synthetic agents such as biguanides, thiazolidinediones,
insulin sensitizers and insulin and these come with consid-
erable side effects, such as hypoglycemia, drug resistance,dropsy and weight gain as well as limited hypolipidemic,
anti-inflammatory and antioxidant activities [6]. Because
they are more effective, safer and affordable, a wide variety
of bioactive components or phytochemicals in foods and
functional foods have become popular and have been
considered as complementary or alternative therapies
for the management and/or treatment of chronic dis-
eases [2, 7, 8]. Moreover, it is reported that in addition
to standard prescribed drugs, a host of complementary
and alternative exotic fruits, herbs, spices and dietary
supplements are widely used in the prevention/treatment
of obesity, diabetes and metabolic syndrome [9–12]. The
purified bioactive compounds and/or whole extract from
medicinal foods have various targets to ameliorate these
health ailments, related complications, hence their burden
on the healthcare.
A wide range of spices is commonly used in the
Cameroon, many of which are native to the country. Apart
from their flavoring characteristics, a number of these
spices are highly valued locally because of their putative
medicinal properties [13, 11]. Tetrapleura tetraptera
(Schumach. And Thonn) Taub, is a leguminous multipur-
pose tree (Mimosoideae) indigenous to tropical Africa. It is
an exotic fruit tree known in Western Nigeria as Aridan. It
is commonly used to prepare several traditional dishes as
popular seasoning spice in western African countries, in-
cluding Ghana, Nigeria and Cameroon while Ghanaians
use the fruit as multivitamins [14]. Compared with other
commonly used spices, it is a rich source of phytochemi-
cals which contribute to its documented biological and
pharmacological activities, including cardiovascular, anti-
inflammatory, hypoglycaemic, hypotensive, neuromuscular,
anti-convulsant, molluscicidal, trypanocidal, hirudinicidal,
anti-ulcerative, ectoxicity, anti-microbial, emulsifying prop-
erty, birth control, food value and the control of intestinal
parasites [15–17]. The nutrients and anti-nutrients content
of Tetrapleura tetraptera fruits have also been reported
[13, 17, 18]. The phytochemical composition in the fruits
of Tetrapleura tetraptera includes polyphenols (tannins,
flavonoids), saponins, phytate, triterpenoid, coumarinic
(scopoletin) and phenolic (caffeic acid, cinnamic acids)
compounds, a triterpene glycoside (aridanin) which have
been found as the active ingredients [7, 17, 19–21]. In a
preliminary study, among water, ethanol and hydro-
ethanolic extracts, the hydroethanolic extract showed
the highest significant blood glucose lowering effect as
well as the highest polyphenolic content. In this study,
we investigated the dose-dependent effect of a hydro-
ethanolic extract of Tetrapleura tetraptera (HET) on
the obese and T2DM rats model (high-carbohydrate
high-fat diet and low-dose streptozotocin (STZ) in-
duced diabetic rats) with characteristics of insulin
resistance, obesity, inflammation, hyperlipidemia, oxi-
dative stress and hypertension.
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Preparation of the polyphenol-rich hydroethanolic extract
of Tetrapleura tetraptera
The dried fruits of TT were bought from the local market
in Yaoundé, Cameroon and identified at the national herb-
arium. Pulps were isolated, ground and extracted using a
mixture of ethanol and water (50:50). Briefly, 5 kg of pulps
were shade dried and powdered, then extracted with 50 %
ethanol for 24 h. After filtration and evaporation of the
solvent, the extract was obtained (450 g).
Experimental animals
Adult male albino rats of Sprague–Dawley (SD) ((180–
210 g), age 6 weeks) strain were used for the experiment.
The animals were housed in polypropylene cages and
maintained under controlled conditions of temperature
(24 () 2 °C) in 12-h light/12-h dark cycles, 50 % humidity.
This study was approved by Institutional Review Board for
animal care and the study was conducted in accordance
with the “Guide for the Care and Use of Laboratory
Animals”
Experimental design and induction of high-carbohydrate
high-fat obese and type 2 diabetic rats
Obesity and T2DM was induced according to the modified
method of Peng et al. [22]. Briefly, male SD rats were accli-
matized and fed a basic chow diet consisting of 7 % fat dur-
ing the first week before experimentation. All animals had
free access to water and food. The rats were divided into
the groups of six as follows: normo lipidic control diet
(NCD), high-carbohydrate high-fat diet (HCHFD),
HCHFD+ HET (HCHFD treated with 200 mg/kg of HET)
(HCHFD200), HCHFD+ STZ (DBC), HCHFD+ STZ +
Metformin (300 mg/kg) (DBMET), HCHFD+ STZ +HET
(low: 200 mg/kg HET) (DB200), and HCHFD+ STZ +
HET (high: 400 mg/kg HET) (DB400). After 7 weeks of
high fat high carbohydrate diet feeding, when the average
body weight reached 410()15 g, the high-carbohydrate
high-fat diet fed rats were divided into HCHFD and
HCHFD+ STZ groups. The latter were injected intraperi-
toneally with a single dose (30 mg/kg bw) of freshly pre-
pared streptozotocin (STZ) in citrate buffer (0.1 M,
pH 4.5). The other groups received only the same amount
of 0.1 M citric acid buffer (pH 4.5). One week later, rats
with a fasting blood glucose level ≥ 11.1 mmol/L were con-
sidered as T2DM rats and used for the experiment. Rats
were then tube-fed for 4 weeks with or without differ-
ent doses of HET (via oral gavage) or metformin (at a
dose of 300 mg/kg, which is in-between those of the
extract), a standard antidiabetic drug used as a positive
control. The same amount of drinking water was used
to serve as the blank. The body weight was measured
weekly throughout the study. Food and water intakes
were measured daily for all rats.During the experiment, rats were fed two control diets:
a normo lipidic control diet, prepared in accordance with
the American Institute of Nutrition [23] AIN-93G, with a
protein concentration of 12 % and a high-carbohydrate
high-fat control diet AIN‐93G-modified, with 12 % (g/g)
protein, 40 % carbohydrate, 35 % (g/g) fat, (4 % (g/g) vege-
table oil (corn) and 31 % (g/g) of animal origin (beef
tallow)) and a drinking solution of 30 % carbohydrate
(sucrose).
The composition of the high-carbohydrate high-fat diet
was as follows (g/100 g food): corn starch, 25;maltodex-
trin, 8,3; corn oil, 4; beef tallow,31; casein (78 % protein),
15.4; sucrose, 6.3; cellulose, 5.0; mineral premix, 3.5; cho-
line bitartrate, 0,2; and vitamin premix, 1; L-cystine 0.3; In
addition to this 30 % sucrose solution was provided as the
drinking fluid to HCHFD rats. The normolipidic control
diet contained corn starch, 47; maltodextrin, 14.2; sucrose,
6.3; corn oil, 7; no beef tallow; normal drinking water, and
the remainder unchanged. Mineral and vitamin mixtures,
as described in AIN-76 were purchased from Harlan
Teklad (Madison, USA). Both STZ injected and non-
injected animals continued on their original diet for the
duration of the study. The vehicle control group received
normal saline. At days 0 and 28 of treatment, blood sam-
ples were collected by the retro-orbital sinus puncture
under chloroform anesthesia. The fasting blood glucose
levels were determined using a glucometer (ONETOUCH,
Ultra, Lifescan, USA). At day 21 oral glucose tolerance test
was performed.
Biochemical analysis
After 28 days of treatment and before sacrifice for organ
collection, the animals were fasted overnight and
weighted, blood samples were then collected by retro-
orbital sinus puncture using capillary under chloroform
anesthesia. Two different tubes with and without anti-
coagulant (heparin) were used for blood collection in
each rat to obtain serum and plasma. Then, serum and
plasma were prepared by centrifuging the blood samples
at 4000 rpm for 15 min. Plasma total cholesterol (TC), tri-
glycerides (TG), and high-density lipoprotein-cholesterol
(HDL-C) were estimated enzymatically using standard kits
(Accurex Biomedical Pvt. Ltd., Thane, India), whereas low-
density lipoprotein-cholesterol (LDL-C) were calculated
based on Friedewald’s equation. LDL-C (mg/dL) = TC-
(HDL-C)- (TG/5). Serum activity of liver function
enzymes: alanine transaminase (ALT/GPT), aspartate
transaminase (AST/GOT), and the concentrations of
total protein, urea and uric acid were estimated by
using kits specific for the each test using a semi-
autoanalyzer (Photometer 5010 V5+, Germany).
The plasma levels of malondialdehyde (MDA), glutathi-
one (GSH), superoxide dismutase (SOD), free fatty acids
(FFA), were determined by using the corresponding assay
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trations of the serum interleukin-6 (IL-6), tumor necrosis
factor-α (TNF-α), C-reactive protein (CRP), leptin, plasma
insulin levels and adiponectin were measured using the
enzyme-linked immunosorbent assay (ELISA) method
using commercially available kits according to the manu-
facturer’s instructions (R&D Systems Inc., Minneapolis,
MN, USA; Millipore Co., Billerica, Massachusetts, USA).
Glycosylated hemoglobin (HbA1C) levels were measured
using commercial NycoCard HbA1C Test kits (Axis-
Shield Company, Oslo, Norway) and a NycoCard HbA1C
Reader II. The Advanced Glycation End Products (AGE)
were determined using the OxiSelect Advanced Glycation
End Product ELISA Kit (Cell Biolabs, CA) according to
the manufacturer’s instructions. All samples and standards
were evaluated in triplicates to ensure accuracy of results.
Measurement of TC, TG and FFA contents in rat liver and
skeletal muscle
At the end of the experiment the animals were eutha-
nized under chloroform anaesthesia and livers and skel-
etal muscles (the quadriceps from the left hind limb of
the animals) were quickly excised off, immediately rinsed
in ice cold saline and stored in liquid nitrogen tank. Por-
tions of these tissues (100 mg) were washed with saline
and homogenized in 2 ml chloroform/methanol (2:1) for
lipid extraction. After homogenization, lipids were fur-
ther extracted by rocking samples for 1 h at room
temperature, followed by centrifugation at 5000 rpm for
10 min. The liquid phase was washed with 0.2 volume of
0.9 % saline. The mixture was centrifuged again at
2000 rpm for 5 min to separate the two phases. The
lower phase containing lipids was evaporated and lipids
were dissolved in 0.5 ml isopropanol containing 10 %
Triton X-100 for TG and TC measurements as described
above.
Determination of insulin resistance
The oral glucose tolerance test (OGTT) was performed
on day 21 on fasted rats. During this fasting period,
fructose-supplemented drinking water in HSHF groups
was replaced with normal drinking water. Blood glucose
was determined at t = 0 through a small incision in the
caudal vein, followed by intra-peritoneal injection of glu-
cose solution 25 % (2 g/kg), 30 min after the administra-
tion of T. tetraptera. The blood glucose was again
measured at 30, 60 and 120 min in order to determine
the glucose level increment. At days 0 (baseline) and 28,
the homeostasis model assessment of insulin resistance
(HOMA-IR) and HOMA-β scores were calculated ac-
cording to the method of Mathews et al. [24] using fast-
ing plasma insulin (FI) and fasting blood glucose (FBG)
concentrations at the baseline and the end of the experi-
mental period according to the following formula:HOMA‐IR ¼ FI μIU=mLð Þ  FBG mmol=Lð Þ½ =22:5
HOMA‐β ¼ 20 FI μIU=mLð Þ½  = FBG mmol=Lð Þ−3:5½ 
Conversion factor: Insulin (1μIU/ml = 0.0417 ng/mL =
7.175pmol/L) and blood glucose (1mmol/L = 18 mg/dl).
Systolic blood pressure measurements
The systolic blood pressure (SBP) of the tail artery was
measured on the 28th day under anesthesia, by non-
invasive blood pressure system MODEL BP-6, Diagnostic
& Research Instruments Co. Ltd., Taoyuan, Taiwan). The
measurements for SBP were recorded in quadruplicates
for each rat and the average systolic blood pressure was
calculated.
Statistical analysis
All results were expressed as median (range) and each
group consisted of 6 rats. Groups were compared by
Kruskal-Wallis test. Differences between two groups were
identified by Mann–Whitney test. P < 0.05 was considered
statistically significant. All the statistical analyses were car-
ried out using the Statistical Package for Social Sciences
version 20 (SPSS Inc., Chicago, USA).
Results
HET possessed a hypoglycemic ability
As shown in Table 1, HCHF diet significantly affects the
blood glucose level, though there was no frank hypergly-
cemia such as in diabetic group (HCHFD + STZ =DBC)
where glycaemia increased to about 3 fold compared
with the normal control (NCD) group. Two hundred
mg/kg dose of HET significantly decreased the high glu-
cose level in obese rats whereas both 200 and 400 mg/kg
doses significantly reduced the diabetic high glucose by
about 50 % and 65 %, respectively. This indicates that
HET possessed a hypoglycemic effect in rats with char-
acteristics of metabolic syndrome. The effect of the
higher dose was even greater than that of metformin
(300 mg/kg).
HET reversed hyperinsulinemia accompanied with obesity
and type 2 diabetes status
Plasma insulin levels were assessed to investigate whether
hyperglycemia status was accompanied with hyperinsuli-
nemia, the prominent feature of type 2 diabetes. The
HCHFD rats had reduced insulin sensitivity (Fig. 1) thus
significant insulin resistance, but T2DM only occurred
after the low-dose STZ injection. In this model, we ob-
served that HCHF diet seemed to elevate the plasma insu-
lin level almost by 2.5 fold whereas this increase was
slightly reduced in HCHFD + STZ though the insulin level
was still significantly higher by about 2-fold as compared
with the NCD. We demonstrated that HET lowered the
Table 1 Fasting blood glucose and fasting insulin of control
and experimental rats at baseline and after 28 days of treatment
with Tetrapleura tetraptera hydroethanolic extract and
metformin
Groups Days FBG (mmol/L) Plasma insulin (μIU/mL)
NCD 0 5.28(4.61–5.94)bc 17.91(16.69–19.75)bc
28 5.39(4.83–5.55)bc 17.88(17.12–19.34)b
T28-T0 −0.23(−0.61–0.94) −0.06(−0.78–0.43)
HCHFD 0 6.97(6.16–7.38)abc 40.3(38.95–45.91)a
28 7.03(6.11–7.44)abc 47.35(44.15–49.13) Sac
T28-T0 0.05(−0.05–0.11) 5.95(2.43–9.37)
HCHFD200 0 6.72(6.27–7.38)abc 39.79(37.23–45.32)a
28 5.44(4.66–6.16)Sbc 22.78(20.39–25.20)Sb
T28-T0 −1.48(−2.11_−0.72) −17.4(−22.3_−13.03)
DBC 0 17.11(12.27–19)a 36.25(34.12–39.23)a
28 16.42(12.22–18.94)a 35.4(34.15–38.87)a
T28-T0 −0.31(−1.33–0.06)a −0.26(−1.2–0.04)
DB200 0 16.55(12.44–18.33)Sabc 37(35.48–38.26)a
28 7.97(6.88–9.4)Sabc 24.74(22.31–27.01)Sabc
T28-T0 −8(−9.39_−5.56) −11.75(−14.91_−9.76)
DB400 0 16.92(13.16–18.45)a 36.15(35.11–39.36)a
28 6.14(5.88_−7.05)Sbc 18.78(16.32–19.88)Sbc
T28-T0 −10.31(−12.57_−7.05) −17.36(−23.04_−15.57)
DBMET 0 16.61(14.44–18.11)a 36.33(35.14–39.15)a
28 6.94(5.77–7.77)Sbc 20.62(19.22–23.15)Sbc
T28-T0 −9.59(−11_−6.83) −16.15(−18.97−13)
Ssignificant compared with T0 (p < 0.05). asignificant relative to normal control
on the same treatment day(p < 0.05). bsignificant compared with HCHFD on
the same treatment day. csignificant compared with diabetic control on the
same treatment day (p < 0.05). (n = 6)
Fig. 1 Effect of HET on OGTT After 21-day HET treatment, rats were fasted
Their blood glucose levels were then measured at 0, 30, 60 and 120 min af
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dose of 200 mg/kg, HET was able to ameliorate the obes-
ity and type 2 diabetes induced hyperinsulinemia in rats,
indicating its potential anti-insulin-resistance property.
The HOMA-IR score was significantly higher in the
HCHFD and DBC groups compared to the NC whereas
the HOMA- β (pancreatic β -cell function) score was
significantly lower in the DBC relative to NCD and
HCHFD groups (Table 2). There was no significant dif-
ference in HOMA- β score between NCD and HCHFD
groups indicating that the pancreatic β -cell function
was not affected in HCHFD groups despite the high
plasma insulin status. Likewise, HET concomitantly
reduced the HOMA-IR score in HCHFD200, DB200 and
DB400 groups and increased the HOMA- β in diabetic
treated groups. It is well known that OGTT is a sensitive
assessment of the early abnormalities in glucose regulation
than fasting blood glucose or glycosylated hemoglobin.
HCHF diet fed rats as well as diabetic rats showed an im-
paired glucose tolerance when compared with normal
control group (Figs. 1 and 2), as indicated by the signifi-
cant difference in blood glucose increment after 30 min.
In our study, oral administration of both HET and metfor-
min to HCHFD and diabetic rats showed a significant
reduction in peak blood glucose level at 30 min in treated
rats during OGTT (p < 0.05). HET (400 mg/kg) had more
pronounced effect than the standard drug (300 mg/Kg).
HET attenuated weight-gain in HCHFD rats
HCHFD rats gained more weight than NCD rats over
the period of 4 weeks. Food intake and water intake
were decreased in HCHFD rats compared with NCD
rats; HET reduced food intake in HCHFD rats without
changing significantly water intake. Energy intake was
increased due to higher energy content of HCHFD diet.
After 28 days of treatment, we noted that the weightovernight followed by intra-peritoneal injection of glucose (2 g/kg).
ter glucose administration
Table 2 HOMA-IR and HOMA- β of control and experimental
rats at baseline and after 28 days of treatment with Tetrapleura
tetraptera hydroethanolic extract and metformin
Groups Days HOMA-IR HOMA-β
NCD 0 4.18(3.66—5.16)bc 200.98(143.36–346-67)bc
28 4.23(3.71–4.77)bc 192.12(186.6–265.41)bc
T28-T0 −0.10(−0.57–0.83) 22.96(−157.98–63.57)
HCHFD 0 12.31(10.78–14.96)abc 243.13(207.99–299.08)bc
28 14.41(12.59–15.86)abc 274.65(230.55–355.33)Sbc
T28-T0 1.8(0.9–2.9) 28.87(9.44–59.39)
HCHFD200 0 11.58(11–14.86)abc 238.48(222.92–284.91)bc
28 5.31(4.85–6.41)Sbc 240.23(153.31–417.24)bc
T28-T0 −6.36(−9.37_−5.38) −5.57(−82.47–189.53)
DBC 0 28.24(21.39–29.41)a 53.34(44.03–89.46)a
28 26.86(21.11–28.75)a 56.04(44.24–89.15)a
T28-T0 −0.64(−3.01–0.13) 0.86(−0.31–3.52)
DB200 0 27.10(20.58–29.96)a 56.68 (49.59–83.27) a
28 8.74(6.82–10.73)Sabc 110.96(85.22–132.01) Sacb
T28-T0 −17.99(−19.22_−13.76) 49.23 (31.78–68.42)
DB400 0 26.63(21.14–32.28)a 54.44 (49.38–74.84)
28 5.32(4.26–5.44)Sbc 142.75 (97.52–157.70) Sbc
T28-T0 −21.23(−28.01_−15.89) 79.00 (48.14–107.25)
DBMET 0 27.40(23.41–29.12)a 59.08 (49.53–66.67) a
28 6.48(5.4–7.28)Sabc 122.11 (93.53–185.55) Sbc
T28-T0 −21.22(−23.11_16.91) 70.99 (26.86–127.90)
Ssignificant compared with T0 (p < 0.05). asignificant relative to normal control
on the same treatment day(p < 0.05). bsignificant compared with HCHFD on
the same treatment day. csignificant compared with diabetic control on the
same treatment day (p < 0.05). (n = 6)
ac
bc bc
ab
Fig. 2 Effect of HET on OGTT. Glucose variation (increment) at different tim
relative to normal control (p < 0.05). bsignificant compared with HCHFD (p
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than its untreated counterpart (p < 0.05) indicating that
body mass increase was significantly suppressed in the
HCHFD200 group compared with the HCHFD group.
Of note, the dose-dependent weight loss that accom-
panied the diabetes status was greater in diabetic
treated rats though not significant. Therefore we hy-
pothesized that T. tetraptera could have a protective ef-
fect again obesity (Table 3).
HET possessed hypolipidemic effects and reduced tissue
steatosis
Hyperlipidemia and related-tissue steatosis are among
the most characteristic feature of T2DM and metabolic
syndrome. These are also two major risk factors that
contribute to the pathogenesis of cardiovascular diseases.
Thus, to understand the effects of HET on lipid metab-
olism, the serum lipid profile and lipid accumulation in
liver and skeletal muscle in T2DM rats were next investi-
gated. As shown in Table 4, serum TG, total cholesterol,
free fatty acids and LDL-cholesterol were considerably
increased in both the HCHFD and HCHFD+ STZ groups
whereas HDL-cholesterol was reduced. The administration
of HET (even at the dose of 200 mg/kg) reduced the serum
level of TG, TC, FFA and increase that of the HDL-
cholesterol. The effects of HET on TG, TC and FFA levels
in livers and skeletal muscles from T2DM rats are pre-
sented in Table 5. A significant increase in liver and
skeletal muscle FFA, TC and TG contents were observed
in obese and T2DM rats and this effect was reversed near
to the normal level by HET treatment (Table 5) in a dose-
dependent manner (p < 0.05). Metformin had no significantc
bc
c
es values at 30,60 and 120 min minus that of baseline. asignificant
< 0.05). csignificant compared with diabetic control (p < 0.05). (n = 6)
Table 3 Body weight at baseline and after 28 days, food and water intakes of control and experimental rats treated with Tetrapleura
tetraptera hydroethanolic extract and metformin
Groups Weight T0 (g) Weight T28 (g) Weight T28-T0 (g) Water intake (mL/day) Food intake (g/day)
NCD 317(309–326)bc 332.5(320–336)Sb 13.5(4–26) 31.6(28.9–32.7)b 28.45(27.6–30.5)bc
HCHFD 414(388–425)a 452.5(445–468)Sa 43(20–63) 23.6(22.1–25.5)a 23.2(21.8–23.9)ac
HCHFD200 412(394–425)a 416(396–442)ab 6.5(−2–17) 21.45(20.6–24.1)a 17.55(16.8–19.4)ab
DBC 414(386–423)a 408(390–422)a −2(−10–4) 22.45(20.6–23.9)a 16.7(15.6–17.5)a
DB200 413.5(390–426)a 410(388–421)a −4(−8–−2) 21.2(20.4–23.4)a 17.6(16.4–18.6)ab
DB400 410.5(392–426)a 398(386–416)a −7(−20–−2) 21.05(20.45–23.7)a 16.4(15.6–17.9)ab
DBMET 407(394–430)a 410(389–430)a −2.5(−5–10) 23(21.4–24.7)a 17.6(16.9–19.5)ab
Ssignificant compared with T0 (p < 0.05). asignificant relative to normal control on the same treatment day (p < 0.05). bsignificant compared with HCHFD on the
same treatment day. csignificant compared with diabetic control on the same treatment day (p < 0.05). (n = 6)
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HDL-cholesterol in the serum compared to the HCHFD,
whereas there was a significant effect on total and LDL
cholesterol.
Besides exhibiting antioxidant ability, HET reduced
glycated hemoglobin and AGE formation
Table 6 represents the levels of plasma HbA1C, MDA,
GSH and SOD in all groups of rats at the end of this
study. In obese and T2DM rats, significant increased
levels of plasma HbA1C, uric acid and MDA and de-
creased levels of GSH and SOD were observed relative
to the normal control. The alteration of these parame-
ters was more pronounced in the diabetic group as
MDA, HbA1C and uric acid levels in the DC rats were
more than 50 % higher than in NC rats. The end prod-
uct of lipid peroxidation, MDA, measured as thiobarbi-
turic acid reactive substances (TBARS) revealed that
obesity and type 2 diabetes enhanced lipid peroxidation,
while HET, especially at a high dose, effectively attenu-
ated lipid peroxidation and suppressed oxidative stress
induced by HCHF diet and STZ, hence exhibiting good
antioxidant capacity. The diabetic status promoted the
Millard reaction and the generation of AGE as the
amount of AGE exceeded 1.5-fold in the HCHFD + STZ
group, compared with the normal control. However, ad-
ministration of 400 mg/kg HET significantly loweredTable 4 Total cholesterol (TC), triglycerides (TG), free fatty acids (FFA
lipoprotein cholesterol (HDL-C) levels in the serum at the end of the
Groups TG (mg/dL) TC (mg/dL)
NCD 86 (79–96)bc 79.5(78–87)bc
HCHFD 173(164–183)ac 139.5(106–120)ac
HCHFD200 113(106–120)abc 109.5(106–120)abc
DBC 205(187–220)ab 169(159–170)ab
DB200 130(119–140)abc 119.5(116–123)abc
DB400 90(86–93)bc 96.5(93–106)abc
DBMET 195.5(176–205)a 129.5(125–137)bc
asignificant relative to normal control (p < 0.05). bsignificant compared with HCHFDAGE generation by 35 % (Table 6) whereas the reduction
of AGE formation by the lower dose was not significant.
Unlike the diabetic group, the increase of glycated
hemoglobin in the HCHFD was not accompanied by a
significant increase in AGE.
HET improved liver and kidney functions
The hepatic injury was assessed by measuring serum
alanine aminotransferase (ALT) and aspartate amino-
transferase (AST) levels. Table 7 shows the levels of AST
and ALT in plasma of normal control, obese rats, dia-
betic rats, and other treatment groups. The activities of
these enzymes were found to be significantly (P < 0.05)
higher in the serum of HCHFD and DBC groups than
those in NCD group suggesting that HCHF and STZ
independently caused hepatic injury in those animals.
HET treatment also reversed the increase of serum ALT
and AST in a dose-dependent manner.
A significant increase in the level of creatinine were
observed in type 2 diabetic rats whereas there were no
significant changes in the urea levels of the animals,
which were all in the normal range.
HET improved inflammatory cytokines levels and
cardiovascular function
To evaluate the effect of HET on inflammation and car-
diovascular function in obese and type 2 diabetes rats,), low density lipoprotein cholesterol (LDL-C) and high density
study
HDL-C (mg/dL LDL-C (mg/dL) FFA (mg/dL)
41.5(39–45)bc 21.9(16.6–26.8)bc 80(75–83)bc
24.5(19–26)a 79.8(78.6–89.2)ac 139.5(136–145)ac
29.5(27–32)abc 57.2(54.6–67)abc 96.5(93–102)abc
20.5(17–23)a 106.6(98.8–112.6)ab 181(169–185)a
31.5(29–36)abc 61.3(57.2–69)abc 139(130–143)ac
43.5(40–45)bc 35.4(30.4–45)abc 80.5(74–86)bc
23.5(21–27)a 66.2(64.4–74.8)abc 146.5(136–150)ac
(p < 0.05). csignificant compared with diabetic control (p < 0.05). (n = 6)
Table 5 Total cholesterol (TC), triglycerides (TG) and free fatty acids (FFA) levels in the liver and skeletal muscle at the end of the study
Liver Skeletal muscle
Groups TG (μg/mg) TC (μg/mg) FFA (μg/mg) TG (μg/mg) TC (μg/mg) FFA (μg/mg)
NCD 80(76–83)bc 40.5(38–45)bc 17.5(15–21) bc 26.50(25–32)bc 24(20–26)bc 4.87(4.5–5.36)bc
HCHFD 172(166–182)a 69(63–78)a 35(32–40)ac 45(41–48)a 39.5(38–42)a 8.16(7.69–8.98)a
HCHFD200 129(115–142)abc 50.5(47–53)abc 25.5(22–30)bc 32(28–36)abc 27(24–28)bc 6.09(5.68–6.4)abc
DBC 173.5(160–187)a 58.5(54–65)ab 43.5(36–48)a 44.5(39_-49)a 38.5(32–43)a 8.21(7.68–8.64)a
DB200 134(118–152)abc 48.5(45–52)abc 30(28–34)ac 29.5(25–33)bc 27.5(26–29)bc 6.1(5.7–6.5)abc
DB400 101(92–120)abc 43(39–46)bc 25.5(23–29)bc 27.5(23–31)bc 20.5(18–24)bc 4.62(4.1–5.8)bc
DBMET 163(150–184)a 41.5(38–45)bc 36.5(34–40)a 36.5(31–40)abc 22.5(20–26)bc 6.73(6.12–7.2)abc
asignificant relative to normal control (p < 0.05). bsignificant compared with HCHFD (p < 0.05). csignificant compared with diabetic control (p < 0.05). (n = 6)
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adiponectin, leptin and systolic blood pressure. Serum
leptin concentrations were increased with HCHF diet
groups compared with NCD whereas the concentra-
tions of adiponectin were higher in the NCD (P < 0.05)
when compared with the groups that received high-
carbohydrate high-fat diet. Treatment with the higher
dose of HET (400 mg/kg) and metformin increased the
adiponectin and reduced leptin. Both adipocyte-derived
hormones were not significantly affected by the lower
dose of HET (Table 8). As depicted in Table 8 the
serum levels of inflammatory cytokines, TNF- α and IL-
6 and CRP levels were significantly increased. The admin-
istration of HET and metformin prevented the increase in
TNF-α, IL-6 and CRP in serum in a concentration-
dependent manner. Systolic blood pressure in HCHF
diet–fed rats was increased as compared with NC diet–fed
rats (Table 8). HET reduced systolic blood pressure in
both HCHF200, DB200 and DB400 rats as compared with
HCHF and DBC rats, respectively.
Discussion
Type 2 diabetes, nonalcoholic fatty liver disease (NAFLD)
and cardiovascular diseases are multiorgan dysfunction
related to long-term metabolic syndrome, which re-
main major public health challenges in modern society
[25]. Unregulated hyperglycemia, hyperlipidemia, oxi-
dative stress, activation of polyol pathway and chronicTable 6 Plasma oxidative stress and antioxidant enzymes in treated
diabetic rats
Groups TBARS (nmol/mg protein) GSH (μmol/L) Plasma uric acid
NCD 5.33(4.98–6.20)bc 34(32–36)bc 31.8(28.9–34.1)bc
HCHFD 9.63(8.79–10.21)a 21(19–23)a 45.35(44.2–45.9)c
HCHFD200 6.92(6.52–8.20)c 27.5(25–29)abc 41.95(41.2–42.5)a
DBC 10.44(9.57–11.20)a 22(19–24)a 56.65(54.8–58.3)
DB200 7.97(6.89–8.26)abc 29.5(27–32)bc 45.95(44.6–47.9)
DB400 5.94(4.6–7.39)bc 33.5(32–36)bc 33.75(32–35.4)bc
DBMET 6.22(4.8–7.36)bc 31.5(29–36)bc 36.3(35.8–37.3)ab
asignificant relative to normal control (p < 0.05). bsignificant compared with HCHFDlow-grade inflammations, induced by sugars and lipids,
delineate the combined sequence of metabolic derange-
ments which may initiate changes in liver, kidneys, pan-
creas and cardiovascular structures and functions then,
ultimately lead to cardiovascular disorders, nephropa-
thy, neuropathy and retinopathy [26]. The risk factors
which include central obesity, elevated blood pressure,
inflammation, impaired glucose tolerance, insulin re-
sistance, and dyslipidemia are also rsesponsible for the
increased morbidity and mortality in humans. It is there-
fore, important to target these established biological alter-
ations for the treatment and reduction of clustering risk
factors of this syndrome. In this study we used a suitable
animal model that mimics all these symptoms of human
metabolic syndrome to test the potential pharmacological
properties of Tetrapleura tetraptera in the management of
obesity, diabetes, hypertension and related metabolic dis-
orders. TT fruit pulp is a culinary spice which has long
been used in traditional medicine to effectively treat dia-
betes and hypertension by local people in Ghana, Yoruba
tribe of Nigeria as well as in southern and western part of
Cameroon. Some researchers have demonstrated the anti-
inflammatory and hyoglycemic properties of TT in a nor-
mal and T1DM Wistar rat model respectively [15]. More-
over, the hypotensive action of scopoletin, a coumarin
isolated from the fruit of T. tetraptera was earlier reported
more than three decade ago [27] in a study in which the
intravenous administration of the compound at the doseand untreated high-carbohydrate high-fat fed and type 2
(μmol/L) SOD(Unit/mg protein) HbA1C(g/kg Hb) AGE (mg/mL)
142(136–146)bc 55.5(50.8–60.1)bc 3.32(2.9–3.5)c
87(82–95) ac 92.25(89.6–96.7)c 3.45(3.1–3.8)c
bc 137(129–144)bc 70.6(67.8–72.6)abc 3.4(2.9–3.7)c
ab 74.5(72–80)b 103.8(99.3–108.3) ab 5.05(4.6–5.3)
ac 131.5(130–134)bc 78.55(76.3–81.5)abc 4.8(4.2–5.1)
135(128–137)bc 51.45(49.3–55.2)bc 3.17(2.9–3.6)c
c 126(122–132)abc 61.05(57.6–62.3)bc 3.75(3.4–4.2)c
(p < 0.05). csignificant compared with diabetic control (p < 0.05). (n = 6)
Table 7 Plasma markers of hepatic and renal function in treated and untreated high carbohydrate high fat fed and type 2 diabetic rats
Groups AST(IU/L) ALT (IU/L) Urea (mmol/L) Creatinine (μmol/L)
NCD 122(119–126)bc 30.5(28–34)bc 5.65(4.60–6.2) 39.95(38.3–41.1)bc
HCHFD 150.5(146–154) ac 56.5(54–59)ac 6.4(5.8–6.6) 47.1(46.2–49) a
HCHFD200 132(129–136)abc 42(38–45)abc 5.75(5.5–6.2) 44.4(43.2–45.7) ac
DBC 162(159–166) ab 66(64–68)ab 6(5.6–7.4) 50.4(48.7–52.9) a
DB200 135(133–138)abc 41.5(39–44)abc 5.7(4.3–6.5) 45.7(44.6–46.9)ac
DB400 122.5(120–126)bc 32.5(31–36)bc 5.65(5.1–5.9) 39.05(36.4–40.3)bc
DBMET 129(126–134)bc 39.5(36–42)bc 5.4(4.5–5.8) 42.4(41.8–44.6)bc
asignificant relative to normal control (p < 0.05). bsignificant compared with HCHFD (p < 0.05). csignificant compared with diabetic control (p < 0.05). (n = 6)
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anaesthetized rats. Subsequent workers also demonstrated
the hypotensive activities of the alcoholic extract of T. tet-
raptera fruits in cats, rats and rabbits [28]. However, the
pattern of disease initiation and development in the
models used in these studies was not closely analogous to
the clinical situation of metabolic syndrome in humans,
with characteristics of obesity, insulin resistance and
hypertension, inflammation, hyperlipidemia and type 2
diabetes mellitus. In addition, this work focuses on the ef-
fects of this spice on high-fat high-fructose diet-induced
weight gain and oxidative stress. In this study, HCHF diet
fed obese rats and experimental T2DM rats induced by
high-fat, high-carbohydrate diet and low-dose STZ pre-
sented with the symptoms as well as the associated com-
plications of metabolic syndrome, including obesity,
dyslipidemia, hypertension and impaired glucose tolerance
followed by partial destruction of the β-cells of the pan-
creas. Thus, this produces a form of obesity and type 2
diabetes analogous to human form of the conditions than
any other available animal model. The cardiovascular and
hepatic complications included inflammation, steatosis
along with increased plasma activities of transaminases.
Indeed, besides presenting with insulin resistance syn-
drome as was characterized by the increased body weight,Table 8 Serum inflammatory markers, systolic blood pressure (SBP)
high-fat fed and type 2 diabetic rats
NCD HCHFD HCHFD200 DBC
CRP (μg/mL) 194.5(168–224)bc 621(589–652)ac 330.5(310–369)
20.77abc
728
IL-6 (pg/mL) 155(139–169)bc 240.5(230–251) a 182(175–192)abc 240
TNF-α
(μg/mL)
544.5(529–569)bc 851.5(816–873) a 657.5(643–670)abc 878
Leptin
(ng/mL)
3.2(2.9–3.8)bc 5.5(4.6–5.9) ac 3.93(3.66–4.36)abc 5.25
adiponectin
(μg/mL)
45.85
(42.9–47.1)bc
22.45
(19.9–24.8) a
32.25(29.7–33.6)abc 25.5
SBP (mmHg) 91(87–96)3.51bc 147.5(142–153) a 113(110–117)abc 141
asignificant relative to normal control (p < 0.05). bsignificant compared with HCHFDhypertriglyceridemia, hypercholesterolemia and com-
pensatory hyperinsulinemia, HCHF fed rats showed
mild hyperglycemia which was converted to frank
hyperglycemia upon administration of low dose of STZ.
As portrayed by the decrease in HOMA- β, this was ac-
companied by decline in secretory capacity of pancreatic
beta cells to compensate for the existing insulin resistance.
The concomitant decreased insulin level was still higher
than that of the normal control. We demonstrated the ef-
fect of HET in lowering blood glucose and ameliorating
insulin resistance. The HOMA-IR was reduced whereas
HOMA-β was increased T2DM treated rats. This observa-
tion implied that HET could exert its hypoglycemic effect
through improving peripheral IR and protecting pancreas
islet β-cells and/or stimulating insulin secretion.
In addition to glucose abnormalities, T2DM patients
are often likely to suffer from cardiovascular diseases as
a consequence of dyslipidemia [29]. Because the insulin
inhibits the hormone-sensitive lipase, IR may contribute
to the development of lipid accumulation in hepatocyte
through impairment of insulin’s capacity to subdue lip-
olysis. This event results in increase in the mobilization
of FFA from the peripheral depots, elevated circulating
FFA and development of hepatocyte steatosis [30]. In
addition, skeletal muscle is another important insulin-and adiponectin in treated and untreated high-carbohydrate
DB200 DB400 DBMET
.5(697–769)ab 350(329–375)abc 129.5(119–153)abc 328(299–356)abc
(235–262)a 198.5(188–201)abc 150(143–160)bc 166(159–173)bc
(847–900)a 605(582–623)abc 543(516–560)bc 595(579–610)abc
(4.8–5.8)a 4.98(4.69–5.3)b 3.9(3.8–4.31)bc 3.12(2.7–3.26)bc
(24.1–28.4)a 24.5(21.6–26.9)a 32.1(28.6–32.9)abc 29.65(28.4–32.1)abc
(139–146)a 129.5(127–133)abc 108(101–112)abc 139.5(134–146)a
(p < 0.05). csignificant compared with diabetic control (p < 0.05). (n = 6)
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tionship between IR in T2DM and both skeletal muscle
steatosis and non-alcoholic fatty liver disease has been
reported [31]. The HCHFD- induced intracellular accu-
mulation of lipid metabolites in the liver and skeletal
muscles further exacerbates insulin resistance through
decreased tyrosine phosphorylation of insulin receptor
substrate, a key mediator in insulin action [32]. Both in-
sulin deprivation and insulin resistance attenuate the ac-
tivity of lipoprotein lipase, a key enzyme in the removal
and degradation of triglycerides from circulation [33].
This leads to hypertriglyceridemia as a result of both in-
creased hepatic VLDL overproduction and impaired
catabolism of triglyceride rich particles. Metabolic disor-
ders such as dyslipidemia are observed in the majority of
T2DM patients and represents an independent risk factor
for the development of coronary heart disease in people
with type 2 diabetes [34]. Likewise, lipid accumulation in
nonadipose tissues could lead to cell dysfunction and/
or cell apoptosis [35]. Previous research demonstrated
that increased hepatocyte apoptosis is a hallmark of
NAFLD in obese individuals [36]. In this study, we ob-
served a significant elevation of TG, TC and FFA levels
in serums, livers, and skeletal muscles of HCHFD obese
and T2DM rats. On the other hand, level of HDL-C in
serum was downregulated in obese and T2DM animals.
HET exhibited a strong activity in the modulation of
lipid metabolism and alleviated these abnormalities in a
dose dependent way. Interestingly, the effect of HET at
the dose 200 mg/kg was greater than that of metformin
(300 mg/kg) in lowering TG and FFA in serum and or-
gans, which in addition to its hypoglycemic effect is poten-
tial to protect patients with metabolic syndrome from
cardiovascular disease.
High-carbohydrate, high-fat diet–induced oxidative
stress has been linked to the initiation of symptoms of
MetS. During the pathogenesis of T2DM, chronic hyper-
glycemia results in increased production of reactive oxy-
gen species (ROS) and appears to constitute the key and
common events in the T2DM [37]. Persistent oxidative
stress may further contribute to the vicious cycle of IR,
in T2DM patients with concomitant increased lipid per-
oxidation as analyzed with TBARS, and altered antioxi-
dant defense [38]. It is reported that increased level of
plasma MDA, an oxidative stress marker, and the re-
duced activities of endogenous antioxidant enzyme SOD
and the level of GSH have been found in T2DM patients
[39]. This observation is consistent with our results,
which showed that in obese and T2DM rats, plasma
levels of GSH and SOD were reduced and that of MDA
was increased as compared to healthy rats. Oral adminis-
tration of HET significantly reduced plasma MDA level
and increased levels of GSH and SOD in a dose-
dependent manner in obese and T2DM rats as comparedto vehicle treatment. In the plasma of the diabetic animals
we also observed an elevation of advanced glycation end
products, and HbA1C, an early product of glycation
process, that accompanied lipid peroxidation. In addition
to its antioxidant effect, HET suppressed the formation of
glycated hemoglobin and AGE, which could be pathogenic
biomarkers in type 2 diabetes-associated vasculopathy.
Liver and kidneys are organs of metabolism and excretion,
and are constantly endowed with the task of detoxification
of environmental pollutants, xenobiotics and chemothera-
peutic agents. AST, ALT, are the major hepatic marker en-
zymes whereas urea and creatinine are markers of renal
function. In the current study, leakage from damaged cells
results in the elevation of hepatic markers in the plasma,
thus, reflected the hepatocyte damage. In another aspect
the significant increase of the creatinine and the non-
significant elevation of urea observed in HCHFD and type
2 diabetic rats indicated modifications in protein catabol-
ism, deleterious effects of free radicals and alterations in
renal function during diabetes. Treatment with HET sig-
nificantly decreased the altered levels of blood AST, ALT,
and creatinine.
We also observed an increase in uric acid, likely due
to the sucrose feeding. In fact, fructose is a component
of sucrose and is distinct from other sugars in its ability
to cause hepatic intracellular ATP depletion (which
stimulates food intake), nucleotide turnover, and the
generation of uric acid [40]. Recent studies showed that
fructose-induced uric acid generation causes mitochon-
drial oxidative stress that alters metabolism and stimu-
lates visceral fat accumulation independent of excessive
energy intake [41]. Epidemiological studies have also
linked fructose intake with hypertension and elevated
fasting uri acid levels [42]. It has been also reported that
long-term feeding of high fructose containing diet causes
nonalcoholic fatty liver disease and hyperlipidemia which
is directly linked to the development of insulin resist-
ance, the first major pathogenesis of T2DM [40]. This
accounts for why fructose intake increases the risk for
metabolic syndrome. Indeed, the intake of higher amounts
of fructose particularly from added sugars, such as table
sugar (sucrose), simple carbohydrates, soft drinks and
high-fructose corn syrup has increased dramatically in the
last century and is largely associated with the rise in over-
weight, obesity, followed by insulin resistance, dia-
betes, and metabolic syndrome in Americans [43].
However, the mechanism by which fructose increases
weight is likely via its ability to stimulate hunger, block
satiety responses, and reduction in resting energy ex-
penditure in overweight and obese subjects [44].
Henceforth, weight gain observed in this study was
driven primarily by increased energy intake from fat
and reduced metabolism rate as a consequence of high
fructose intake induced leptin resistance in rats [44].
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and leptin secreted mainly by adipose tissue are
present in adipocytes and serum [3, 45]. Serum levels
of leptin are strongly associated with fat mass, BMI
and leptin resistance in obesity and also tend to in-
crease in diabetes, hypertension, hyperlipidemia, and
ischemic heart disease [3, 45]. This was consistently
observed in our study where leptin levels clearly in-
creased whereas adiponectin decreased in the HCHFD
groups compared with the NCD groups. Besides, leptin
is also involved in the regulation of energy balance and
production of inflammatory cytokines [46].
Chronic low-grade inflammation is believed to play an
important pathogenetic role in the development of IR
and T2DM and it is therefore closely related to reduced
insulin sensitivity [47]. C-reactive protein,, an acute-
phase protein, is an inflammatory marker synthesized
and released by the liver under the stimulation of cyto-
kines such as TNF- α and IL-6 [48]. Earlier studies have
demonstrated that CRP, TNF-α and IL-6, circulating
markers of low-grade inflammation and vascular injury,
are strong predictors of increased risk for T2DM [49].
On the other hand, adiponectin is inversely correlated
with obesity and has a protective effect against insulin re-
sistance as it exhibits anti-inflammatory properties by re-
ducing TNF-α and IL-6 secretion from macrophages [50].
Our results indicated that significant increases in the levels
of pro-inflammatory cytokines, TNF- α IL-6 and also CRP
were observed in obese and type 2 diabetic rats and were
consistent with other studies [3, 5, 6, 45, 51]. Upon admin-
istration of HET, we observed a significant reduction in
serum cytokine levels and CRP associated with a decrease
in insulin resistance.
Another leading risk factor for cardiovascular and
renal morbidity and mortality is hypertension. It is also
one of the major contributors to global disease burden
(4.5 %) and is prevalent in both developing countries
and the developed world [52]. In obesity, adipocytes also
expressed angiotensinogen, leading to an angiotensin
II–induced increase in blood pressure [53]. Besides redu-
cing weight gain, the hypotensive effect of HET in obese
and type2 diabetic rats observed in this study, corrobo-
rated earlier reports by other abovementioned researchers.
Studies have found that T. tetraptera fruit is a reser-
voir of medicinal phytochemicals with wide range of po-
tential application [21, 17]. For instance, it has been
reported that the pulp of dried fruits contains about 1 to
20 % of saponins, 2.5 % of flavonoids, 0.12 % of tannins,
1 % alkaloids 5 % phytates, and 5–11.36 % of fibers [17],
among which flavanoids and saponins, fibers, and at a
lesser extent phytates are well known for at least one of
the following antidiabetic, anti-inflammatory, antioxidant
and anti-obesity properties [5, 7, 51]. Of note, Fleischer
et al. [54] have recently isolated three flavonoids from thefruits of Tetrapleura tetraptera, which were the first
reported isolation of such constituents from the genus
Tetrapleura. In addition, the isolated flavonoids have dem-
onstrated various biological activities. For Instance, 2’ , 4’ ,
4-tetrahydroxychalcone (butein) has been shown to be a
potent antioxidant and an anti-inflammatory agent [55].
Secondly, 2’ ,4,4’-trihy-droxychacone (Isoliquiritigenin) has
exhibited vasorelaxant effect on the phenylephrine-
precontracted rat aorta [56], aldose reductase inhibiting
property [57] and is also a potent anti-tumor and anti-
inflammatory agent [58]. The third isolated compound 4’ ,
5, 7-trihydroxy-flavanone (Naringenin) has been reported
to lower plasma cholesterol in vivo [59] and also has anti-
oxidant and blood glucose lowering activities [60]. There-
fore the presence of these constituents in the fruit of T.
Tetraptera could have contributed to the observed anti-
oxidant, anti-inflammatory, hypolipidemic, hypoglycaemic
and hypotensive effects of the extract in our study.
In conclusion, the results of this study provides the
scientific rationale for some of the numerous uses of
Tetrapleura tetraptera fruit as in the management of
type 2 diabetes, inflammation and cardiovascular dis-
eases like hypertension and stroke in some folkloric soci-
eties of Cameroon, Nigeria and Ghana. Besides, it has a
protective effect against diet-induced obesity.
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